New York, NY (PRWEB) April 02, 2013
Clinilabs, an early phase and specialty CRO that provides clinical drug development services to industry, today announced that it has launched a subject authentication initiative at its Phase 1 sites in New York and New Jersey. This initiative includes the authentication of subject identity and medical history, background checks, and tracking of prior study participation in order to eliminate ineligible subjects from clinical trials. The Company has selected Verified Clinical Trials (VCT) to assist with this initiative, implementing the VCT clinical trials database registry system. VCT’s registry is designed to stop the professional research subjec t from enrolling in multiple clinical trials simultaneously – a situation known as dual enrollment. This collaboration between Clinilabs and VCT is a reflection of both companies’ commitment to volunteer safety and data quality.
Failure to document the identity of study volunteers, inaccuracies in subjects’ medical histories, and multiple concurrent enrollments have become a serious problem in the clinical research world. Study volunteers interested in free care or compensation may present inaccurate information in order to gain entry to clinical trials, and some may jump from one study to another without waiting for enough time to lapse between treatments. This type of research volunteer places everyone at risk including the drug manufacturer, the research site, and most importantly, themselves, potentially jeopardizing their health. Furthermore, this may compromise data quality.
Copyright©2012 Vocus, Inc.
All rights reserved